Syqe Medical launched its pharmaceutical-grade metered-dose cannabis inhaler in Israel after a recently regulatory approval.
The Tel Aviv-based pharma-tech company spent eight years researching the inhaler technology and testing it in multiple clinical trials. Syqe Medical says the drug delivery technology could introduce complex respiration technique automation, electronic selective dosing and remote clinical monitoring and dose control, well beyond the use of cannabis.
“Eighty percent of cannabis patients inhale the plant. For too long, physicians who wish to treat these patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events in cannabis,” founder & CEO Perry Davidson said in a press release. “For eight years, Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly.”
The Syqe Inhaler is a non-combustion drug delivery device that has received regulatory approval from the Israeli Ministry of Health as a medical device that uses cannabis. The devices will be marketed and distributed by Teva Israel and will be produced under controlled pharmaceutical conditions.